BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18436722)

  • 1. Treanda approved for chronic lymphocytic leukemia.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine (Treanda) for CLL and NHL.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
    [No Abstract]   [Full Text] [Related]  

  • 3. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs: Ciclesonide, certolizumab pegol, and bendamustine hydrochloride.
    Hussar DA
    J Am Pharm Assoc (2003); 2008; 48(4):557-61. PubMed ID: 18653436
    [No Abstract]   [Full Text] [Related]  

  • 7. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
    Friedberg JW
    Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I studies with bendamustine: an update.
    Schrijvers D; Vermorken JB
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):15-8. PubMed ID: 12170427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Elefante A; Czuczman MS
    Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
    Lissitchkov T; Arnaudov G; Peytchev D; Merkle Kh
    J Cancer Res Clin Oncol; 2006 Feb; 132(2):99-104. PubMed ID: 16292542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine in the treatment of hematologic malignancies. Introduction.
    Diehl V; Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
    [No Abstract]   [Full Text] [Related]  

  • 14. Bendamustine therapy in chronic lymphocytic leukemia.
    Masiello D; Tulpule A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine.
    Keating MJ; Bach C; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Jun; 7(6):473-4. PubMed ID: 18511926
    [No Abstract]   [Full Text] [Related]  

  • 16. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
    Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
    Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
    Cheson BD
    Leuk Res; 2014 Nov; 38(11):1267-8. PubMed ID: 25260826
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
    Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
    Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
    Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug essentials. An alkylating agent for CLL and NHL.
    Wilkes GM
    Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):55-6. PubMed ID: 19856600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.